PubMed ID:
34930868
Public Release Type:
Journal
Publication Year: 2022
Affiliation:
Division of Cardiology, b
Division of Nephrology, c
Division of Endocrinology, Diabetes
and Metabolism, Department of Medicine, University of Verona, Verona and d
DepartDepartment of Pharmaceutical Sciences, School of Specialization in Hospital Pharmacy, University of Milan, Milan, Italy
DOI:
https://doi.org/10.1097/HJH.0000000000003066
Authors:
Gambaro G,
Bignaminid AA,
Mantovanic A,
Lombardib G,
Ribichinia FL,
Gambaroa A
Request IDs:
23180
Studies:
The HALT Progression of Polycystic Kidney Disease
Blood pressure control, which can induce a slight decrease in the glomerular filtration rate (GFR), plays a nephron- and cardioprotective role. However, the more important early decline in GFR associated with antihypertensive therapy and strict blood pressure targets is still of concern. Since few data are available from trials and observational studies, and the phenomenon is relatively rare, we performed a metaanalysis of available studies. We conclude that major reductions in the glomerular filtration rate occurring soon after starting angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and/or under intensive blood pressure control predict end-stage kidney disease